BOSTON SCIENTIFIC CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.1 | $16.7 | $14.2 | $12.7 | $11.9 |
| Operating income | $3.6 | $2.6 | $2.3 | $1.6 | $1.2 |
| Net income | $2.9 | $1.8 | $1.6 | $0.7 | $1.0 |
| Balance Sheet | |||||
| Total debt | — | $10.7 | $9.1 | $8.9 | $9.1 |
| Cash Flow Statement | |||||
| Free cash flow | $3.7 | $2.6 | $1.8 | $0.9 | $1.3 |
| Dividends | — | $0.0 | $<0.1 | $0.1 | $0.1 |
| Share repurchases | — | — | — | $0.0 | $0.0 |
Shares outstanding 1.4B · Free float 99.8%
Annual filing data through FY ended December 31, 2025; float as of September 22, 2026.
Earnings
Other Coverage
October 6, 2026
FDA
Boston Scientific Recalls Imager II Angiographic Catheters
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 17, 2026
FDA
Boston Scientific Recalls ENROUTE Transcarotid System
September 17, 2026
FDA
Boston Scientific Recalls ENROUTE Transcarotid System
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 7, 2026
Insider Signal
Insiders Buy Into Boston Scientific Restructuring